Analysis of the working principle of cabozantinib in targeted therapy

Cabozantinib is a multi-target small molecule tyrosine kinase inhibitor. It can inhibit a variety of targets related to tumor cell growth and angiogenesis, including MET, VEGFR1, VEGFR2, RET, AXL, NTRK, KIT and other proteins. By inhibiting the activity of these kinases, cabozantinib can block the signal transduction pathways in tumor cells, thereby inhibiting the proliferation, migration and invasion of tumor cells, and achieving anti-tumor effects.

Cabozantinib exerts its anti-tumor effects by inhibiting tyrosinase activity. It kills tumor cells, reduces metastasis, and inhibits tumor angiogenesis. The drug was initially approved by the U.S. Food and Drug Administration for the treatment of metastatic medullary thyroid cancer and has shown significant anti-tumor effects. In addition, cabozantinib has also been approved for advanced renal cancer that has failed first-line anti-angiogenic drugs, further demonstrating its important position in targeted therapy.

The indications of cabozantinib mainly include thyroid cancer, renal cancer, etc., but it can also be used to treat other types of tumors, such as liver cancer and non-small cell lung cancer. In practical applications, cabozantinib can be used in combination with other drugs to improve the therapeutic effect. For example, it can be used in combination with immunotherapy drugs to improve the effectiveness of immunotherapy by reshaping the tumor microenvironment and turning cold tumors into hot tumors.

Although cabozantinib plays an important role in targeted therapy, it may also cause some adverse reactions, such as hypertension, proteinuria, and osteonecrosis of the jaw. Therefore, when using cabozantinib, it is necessary to pay close attention to the patient's response and adjust the treatment plan in a timely manner. In addition, cabozantinib should be contraindicated in certain populations, such as patients with active peptic ulcer disease, inflammatory bowel disease, or uncontrolled infection.